Urology Medical News about Prostatic Hyperplasia Naftopidil

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia
Cochrane Reviews, 10/19/09

Garimella PS et al. – This review of eight trials evaluated naftopidil for the treatment of BPH. Current evidence is sparse. The authors did not identify any placebo–controlled trials. Naftopidil had a similar short–term efficacy and adverse–effect profile compared to low–dose tamsulosin, and better efficacy than phytotherapy (eviprostat). Adverse effects of naftopidil were few, most commonly dizziness and hypotension. Prior to wide–spread use, more long–term, randomized, controlled studies compared to standard therapy are needed.

<< Previous
Financial Risk of the Biotech Industry versus the Pharmaceutical...

Next >>
A Prospective Study of Risk Factors for Nephrolithiasis After...